title: [Comparative analysis of arterial bioprostheses with various antithrombotic modification].
abstract: The present study was aimed at comparing the results of remote patency ol arterial bioprosthcses «KemAngioprosthesis» in infrainguinal position with various antithromhotic modifi cation. We analyzed the outcomes in a total of 133 patients who were subdivided into two groups: Group I (n=91) underwent implantation of hioprostheses with antithrombotic modifi calion by non-fractionated heparin. and Group II (n=42) received prostheses treated with low-molecular-weight heparin «Clexane». Patients of the both groups underwent comprehensive analysis of the haemostatic system, blood plasma lipid spectrum, as well as duplex scanning of the prosthesis. 39 (42.9%) Group I patients and 6 (13.6%) Group II patients were found to have developed thromboses. Besides, 14 (I5.4%) Group I patients were diagnosed as hawing restenosis of the anastomosis site, with this complication observed in 3 (7.3%) Group II patients. The results of the analysis demonstrated better remote patency of bioprostheses with antithromhotic modifi cation by low-molecular-weight heparin «Clexane». Dynamic follow up of the patients made it possible to carry out timely correction of medicamentous therapy, as well as at early stages to reveal restenosis of anastomoses followed by endovascular correction.
authors.forename: L S
authors.initials: LS
authors.lastname: Barbarash
authors.forename: N N
authors.initials: NN
authors.lastname: Burkov
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Kudriavtseva
authors.forename: A I
authors.initials: AI
authors.lastname: Anufriev
authors.forename: I Iu
authors.initials: IIu
authors.lastname: Zhuravleva
mesh_terms: D001682:Biological Availability; D001705:Bioprosthesis / Q000009:adverse effects*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D057186:Comparative Effectiveness Research; D016503:Drug Delivery Systems / Q000379:methods; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006493:Heparin